Expressed in lei, the half-year growth was also of 3.5%.

“The forecast remains modest. The initial growth forecast of +1.4% in lei for 2013 has been halved to +0.7%, following half-year financial reports. Considering the moderate update of the list of compensated drugs, Cegedim forecasts a growth of +2.7% in lei for 2014,” Cegedim Romania general manager Petru Craciun said in a press release Friday.

By distribution channels, drug sales in pharmacies rose 3.5% to EUR1.16 billion, while sales in hospitals increased by 3.1% to EUR180 million in January through June. Prescription drugs reached sales of EUR962.6 million in the first six months, up 2.4% on the year, while over-the-counter drug sales stood at EUR201.5 million, up 9.1%.

The total value of medicines sold to patients reached EUR647.5 million in the second quarter of 2013, up 3.4% from the same period in 2012. Expressed in lei, the growth was of 2.7% to RON2.84 billion.

“Compared to growth rates in the past five quarters, the second quarter of 2013 saw a slight increase in units (2.7%), in days of treatment (3.3%) and in lei (2.7%),” according to Cegedim.

In the past 12 months (July 2012 and June 2013), the local pharmaceutical stood at RON11.92 billion, up 4% from the year-earlier period. Expressed in euros, the market rose 1.4% to EUR2.67 billion.

According to Cegedim, French group Sanofi-Aventis (including Zentiva) remains the market leader in Romania, with sales of RON925.2 million (a 7.8% market share), followed by Hoffmann La Roche, with sales of RON875.8 million (a 7.3% market share), and Novartis with sales of RON735.9 million (a 6.2% market share).

The next seven spots are taken by Servier, Pfizer, GlaxoSmithKline, Merck & Co, AstraZeneca, Ranbaxy and Abbott, with market shares between 3.6% and 5.7%.

The ranking from 11 to 20 includes KRKA, Antibiotice, Johnson&Johnson, Teva, Menarini, Bristol Myers Squibb, Alvogen, Bayer, Eli Lilly and Gedeon Richter, with market shares between 1.4% and 2.6%.